A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies
Authors
Keywords
-
Journal
LEUKEMIA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-12-11
DOI
10.1038/s41375-019-0652-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
- (2018) Courtney D DiNardo et al. LANCET ONCOLOGY
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- (2017) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
- (2017) T-C Teh et al. LEUKEMIA
- From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
- (2017) Avi Ashkenazi et al. NATURE REVIEWS DRUG DISCOVERY
- Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition
- (2017) Joyoti Dey et al. Scientific Reports
- Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia
- (2016) Yixiang Chen et al. BRITISH JOURNAL OF HAEMATOLOGY
- Overview of CDK9 as a target in cancer research
- (2016) Fatima Morales et al. CELL CYCLE
- Genetic and epigenetic heterogeneity in acute myeloid leukemia
- (2016) Sheng Li et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members
- (2016) S. J. Hogg et al. MOLECULAR CANCER THERAPEUTICS
- The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
- (2016) András Kotschy et al. NATURE
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- New targeted therapies for malignant lymphoma based on molecular heterogeneity
- (2016) Heike Horn et al. Expert Review of Hematology
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells
- (2016) Juraj Bodo et al. Oncotarget
- The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia
- (2015) A. Baker et al. CANCER RESEARCH
- Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1
- (2015) L Li et al. LEUKEMIA
- Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia
- (2015) Mark C. Lanasa et al. LEUKEMIA RESEARCH
- MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor
- (2015) Y. Xiao et al. MOLECULAR CANCER THERAPEUTICS
- Getting up to speed with transcription elongation by RNA polymerase II
- (2015) Iris Jonkers et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
- (2015) Joel D. Leverson et al. Science Translational Medicine
- Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
- (2015) J D Leverson et al. Cell Death & Disease
- Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
- (2015) D C Phillips et al. Blood Cancer Journal
- CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo
- (2015) G P Gregory et al. LEUKEMIA
- Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53
- (2014) G. L. Kelly et al. GENES & DEVELOPMENT
- MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis
- (2014) Robert N. Booher et al. PLoS One
- Many players in BCL-2 family affairs
- (2014) Tudor Moldoveanu et al. TRENDS IN BIOCHEMICAL SCIENCES
- Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma
- (2013) Jeffrey A. Jones et al. AMERICAN JOURNAL OF HEMATOLOGY
- A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
- (2013) John J Nemunaitis et al. Journal of Translational Medicine
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
- (2012) S. P. Glaser et al. GENES & DEVELOPMENT
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms
- (2011) B. Holkova et al. CLINICAL CANCER RESEARCH
- Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases
- (2011) Andreas Strasser et al. EMBO JOURNAL
- Ubiquitin-Independent Degradation of Antiapoptotic MCL-1
- (2010) D. P. Stewart et al. MOLECULAR AND CELLULAR BIOLOGY
- Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations
- (2009) E. Leich et al. BLOOD
- Selective control of gene expression by CDK9 in human cells
- (2009) Judit Garriga et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
- (2009) Thomas S. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started